novel avian influenza subtype ahn emerge metres public health threat tandem potent previous shown dna vaccine prime increase magnitude quality antibody response hn monorail inactive boost report safety immunogen h drawn primeboost regimen phase open label random clinic trial value three vaccine regimen health adult inter week group receive prime homolog overall individual year old enroll complete vaccine inject well tower serious adverse event postboost achieve hai tier compare also least fourfold increase neutral seen subject peak geometry mean tier significantly greater gt p safe welltoler immunogen boost higher along 